The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

WASHINGTON -- The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the first step in an anticipated global rollout that could ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...